2008 | 2007 | 2006 | 2005 | 2004 | 2003
|
| November 16, 2004 |
 Vasogen Announces Full Patient Enrollment in its Pivotal Phase III Trial of Celacade™ in Peripheral Arterial Disease |
 |
| October 27, 2004 |
| Vasogen’s VP025 Prevents Detrimental Effects of Beta-Amyloid in Preclinical Model of Cognitive Dysfunction |
|
| October 26, 2004 |
| Vasogen’s VP025 Provides a Neuroprotective Effect in Preclinical Model of Parkinson’s Disease |
|
| October 25, 2004 |
| ALS Researchers Deliver Oral Presentation of Vasogen’s VP025 at Neuroscience 2004 |
|
| October 21, 2004 |
| Vasogen To Present at Rodman and Renshaw Techvest 6th Annual Healthcare Conference |
|
| October 13, 2004 |
| Vasogen Announces Third Quarter 2004 Results |
|
| October 7, 2004 |
| Vasogen to Conduct Quarterly Conference Call |
|
| October 4, 2004 |
| Vasogen’s VP025 Delays Disease Onset and Prolongs Survival in Preclinical ALS (Lou Gehrig’s disease) Model |
|
| September 21, 2004 |
| Vasogen To Present at UBS Global Life Sciences Conference |
|
| September 15, 2004 |
| Vasogen’s Celacade™ Reduces Cardiac Inflammation |
|
| September 15, 2004 |
| Vasogen’s Phase II Chronic Heart Failure Results Published in the Journal of the American College of Cardiology |
|
| September 1, 2004 |
| Vasogen To Webcast R & D Investor Meeting |
|
| July 14, 2004 |
| Vasogen Announces Second Quarter 2004 Results |
|
| July 12, 2004 |
| Vasogen’s VP025 Reverses Age-Related Memory & Learning Impairment in Preclinical Model |
|
| July 9, 2004 |
| Vasogen to Conduct Quarterly Conference Call |
|
| June 24, 2004 |
| Vasogen Research Published in the Journal of Neuroimmunology |
|
| June 22, 2004 |
| Vasogen’s Phase II Heart Failure Results Accepted for Publication in the Journal of the American College of Cardiology |
|
| June 15, 2004 |
| Vasogen Provides Update on Phase III Clinical Programs |
|
| June 14, 2004 |
| Vasogen To Present at Needham & Company Biotechnology Conference |
|
| June 3, 2004 |
| Vasogen To Present at BIO 2004 |
|
| May 17, 2004 |
| Vasogen Added to NASDAQ Biotechnology Index |
|
| May 3, 2004 |
| Vasogen’s VP025 Reduces Brain Injury in Preclinical Model |
|
| April 14, 2004 |
| Vasogen Announces First Quarter 2004 Results |
|
| April 8, 2004 |
| Vasogen to Conduct Quarterly Conference Call |
|
| March 4, 2004 |
| Vasogen Announces Closing of US$57.7 Million Common Share Offering |
|
| February 27, 2004 |
| Vasogen Prices Public Offering of Common Shares |
|
| February 9, 2004 |
| Vasogen Announces Offering of Common Shares |
|
| February 9, 2004 |
| Vasogen Announces 2003 Year-end Results |
|
| February 2, 2004 |
| Vasogen Receives CE Mark for Celacade™ in Europe for the treatment of Chronic Heart Failure |
|
Home 
Contact Us 
Search 
Site Map 
Printable Page